← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cardiac Rsk3 Inhibitors, Llc
Los Altos, CA
$10,485,488
Total funding
3
Grants
Funding over time
peak $3.2M · FY2019–24$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,485,488 · 3
By mechanism
R44$10,485,488 · 3
Investigators at Cardiac Rsk3 Inhibitors, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
RSK3 Anchoring Disruptor Therapy for Heart Failure$1,982,787
R44 · FY2024 · HL
RSK3 Anchoring Disruptor Therapy for Heart Failure$1,978,293
R44 · FY2023 · HL
PP2A Anchoring Disruptor Therapy in Heart Failure$1,888,812
R44 · FY2022 · HL
ShRNA-Based Targeting of mAKAPò in Heart Failure$1,761,984
R44 · FY2021 · HL
PP2A Anchoring Disruptor Therapy in Heart Failure$1,219,206
R44 · FY2023 · HL
ShRNA-Based Targeting of mAKAPò in Heart Failure$885,032
R44 · FY2022 · HL
PP2A Anchoring Disruptor Therapy in Heart Failure$436,929
R44 · FY2021 · HL
ShRNA-Based Targeting of mAKAPò in Heart Failure$332,445
R44 · FY2019 · HL